Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMT/SCT for Hematologic Malignancies and Solid Tumors
NCT00060255Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 1991
- Primary completion
- Aug 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of etoposide, cyclophosphamide, carmustine, melphalan, busulfan in hematologic malignancy, solid tumor, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), sponsored by Roswell Park Comprehensive Cancer Center. Started Dec 1991; status: completed.
02
Drugs
etoposidecyclophosphamidecarmustinemelphalanbusulfan
03
Conditions
hematologic malignancysolid tumoracute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00060255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060255.